| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 2000: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Research Abstract |
Rebamipide, which is used as a drug for gastritis and gastric ulcer, has large capability for OH radical scavenging. It is expected that rebamipide may have a protective effect against radiation enteritis after pelvic irradiation.
Thirty-two patients receiving pelvic radiation therapy were randomized to rebamipide 300 mg, three tablets three times daily, or no drug. The severity of the acute radiation bowel reaction was documented by a weekly questionnaire. The Grade 0, 1, 2, 3, and 4 bowel toxicity was obseved in 4 versus 2 patients, 4 versus 3, 6 versus 8, 2 versus 4, and 0 versus 1 in the rebamipide and no-drug arms, respectively. Rebamipide seemed to be effective for diarrhea occurring during pelvic radiation therapy, but there was no statistically significant.
The colorectum of C3H mice, after administration of rebamipide, were irradiated using a dose of 30 Gy and prepared for histology 15 days following irradiation. However, no significant differences were observed in mice with or without rebamipide administration.
|
